A randomized phase II trial of a vaccine combining tyrosinase /gp100 peptides emulsified with montanide ISA 51 alone or with a block co-polymer CRL 1005 or with GM-CSF for patients with resected stages IIA and IIB melanoma grant application title: MART-1/gp100 immune responses to a melanoma vaccine
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine; Montanide ISA-51; Sargramostim
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 May 2014 Biomarkers information updated
- 02 Nov 2005 New trial record.